Treatments modalities for subcutaneous calcinosis
| Treatment modality | No | Diagnosis | Outcome | Reference |
|---|---|---|---|---|
| *As indicated by increase in subcutaneous calcinosis per clinical and radiograph evaluation; †in a follow up of 8–63 months, as rated by patients; ‡defined as relief of pain and improvement in function; §as indicated by increase in subcutaneous calcinosis per clinical and radiograph evaluation; ¶in a follow up of 8–63 months as rated by patients. | ||||
| Disodium etidronate | ||||
| 10 mg/kg | 3 | Dermatomyositis | 5/6 Progression* | Metzger et al (1974)5 |
| >20 mg/kg | 3 | Scleroderma | ||
| Alendronate 10 mg/kg | 1 | Juvenile dermatomyositis | Clinical and radiological response | Mukamel et al(2001)6 |
| Alendronate | 1 | Juvenile dermatomyositis | Clinical and radiological response | Oliveira and Wolff (2003)7 |
| Aluminium hydroxide | ||||
| 120 ml/day | 1 | No change—short follow up | Hudson et al (1974)8 | |
| Surgical removal | 7 | Scleroderma | 6/7 Beneficial† | Mendelson et al (1977)9 |
| Carbon dioxide laser | 6 | Systemic sclerosis | 3 Good response‡ | Bottomley et al (1996)10 |
| 2 Moderate response | ||||
| 1 Poor response | ||||
| Intralesional adrenal steroids injection | 1 | Scleroderma | Smaller and less painful ulcer after 3 months | Hazen et al (1982)11 |
| Diltiazem | ||||
| 120 mg/day | 1 | Scleroderma | Dramatic improvement at follow up of 2 years | Dolan et al (1995)12 |
| 180 mg/day | 12 | Scleroderma | 6 Unchanged§ | Vayssairat et al (1998)13 |
| 3 Slight regression | ||||
| 3 Intensification | ||||
| Minocycline | 9 | Scleroderma | 8 Improvement in the incidence of ulceration and inflammation | Robertson et al (2003)14 |
| 1 Radiographic improvement | ||||
| Warfarin | ||||
| 1 mg/day phase I | 4 | Dermatomyositis | 1 Improvement in bone scan | Berger et al (1987)2 |
| Scleroderma | 1 Improvement in bone scan and plain film | |||
| 2 No change | ||||
| 1 mg/day phase II | 8 | Placebo treatment | 2/3 Treatment group had improvement in bone scan scores | |
| 0/4 Placebo group showed improvement | ||||
| Warfarin 1 mg/day | 6 | Dermatomyositis | 5 Worsening¶ | Lassoued et al (1988)3 |
| Scleroderma | 1 Stable | |||
| Warfarin 1 mg/day | 1 | Scleroderma | Clinical and radiographic improvement | Yoshida and Torikai(1993)4 |
| Anti-TNF | 2 | Idiopathic inflammatory myositis | Regression and non-tender in follow up of 6–14 months | Maillard (2002)15 |
| Anti-TNF | 2 | Juvenile dermatomyositis | No progression and non-tender in follow up of 2–10 months | Maillard et al (2001)16 |